

10 June 2021

Rebecca Fuller

Via email: Rebecca@navigatenorth.co.nz



100 Heads Road, Private Bag 3003
Whanganui 4540, New Zealand

Tēnā koe Rebecca

Official Information Act Request – OIA 13481 PSMA Funding

On 11 May 2021, under section 12 of the Official Information Act, you requested the following information from Whanganui District Health Board (WDHB):

Please can you advise whether PSMA (Prostate Specific Membrane Antigen) PET-CT is funded by the DHB or only available privately?

If publicly funded, please can you advise whether there are criteria that must be met.

For example:

- For staging of high risk and unfavourable intermediate risk prostate cancer before definitive local therapy.
- For restaging of PSA recurrence (0.2ng/ml)."

Whanganui District Health Boards response:

Please can you advise whether PSMA (Prostate Specific Membrane Antigen) PET-CT is funded by the DHB or only available privately?

Whanganui DHB confirms PET-CT is funded by the DHB.

If publicly funded, please can you advise whether there are criteria that must be met.

For example:

- **For staging of high risk and unfavourable intermediate risk prostate cancer before definitive local therapy.**
- **For restaging of PSA recurrence (0.2ng/ml)."**

A PSMA CT scan may be requested by the providing clinician in the situations of:

- Biochemical (≥ 0.5 post prostatectomy or > 2.0 post radical radiotherapy) or indeterminate conventional imaging findings suggestive of recurrent/metastatic prostate cancer or
- High risk factors suggestive of metastatic prostate cancer in the untreated patient (stage T3a-T4, gleason 8-10, PSA > 20)

Should you have any further queries about the above information, please contact our OIA co-ordinator Anne Phoenix at anne.phoenix@wdhb.org.nz

Ngā mihi

Russell Simpson
Chief Executive